Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Language
Affiliation country
Publication year range
1.
Med Mycol ; 59(5): 476-485, 2021 May 04.
Article in English | MEDLINE | ID: mdl-32823281

ABSTRACT

Drug repositioning has been an important ally in the search for new antifungal drugs. Statins are drugs that act to prevent sterol synthesis in both humans and fungi and for this reason they are promissory candidates to be repositioned to treat mycoses. In this study we evaluated the antifungal activity of atorvastatin by in vitro tests to determine the minimum inhibitory concentration against azole resistant Candida albicans and its mechanisms of action. Moreover, the efficacy of both atorvastatin-loaded oral and vaginal emulgels (0.75%, 1.5% and 3% w/w) was evaluated by means of in vivo experimental models of oral and vulvovaginal candidiasis, respectively. The results showed that atorvastatin minimal inhibitory concentration against C. albicans was 31.25 µg/ml. In oral candidiasis experiments, the group treated with oral emulgel containing 3.0% atorvastatin showcased total reduction in fungal load after nine days of treatment. Intravaginal delivery atorvastatin emulgel showed considerable effectiveness at the concentration of 3% (65% of fungal burden reduction) after nine days of treatment. From these findings, it is possible to assert that atorvastatin may be promising for drug repositioning towards the treatment of these opportunistic mycoses.


Atorvastatin is a statin drug that presents antifungal activity. This study showed that atorvastatin-containing oral and vaginal emulgels were able to treat vulvovaginal and oral candidiasis of infected animal model. Therefore, we showcased that atorvastatin may be a possible therapeutic agent in order to be a used to control opportunistic mucosal fungal infections caused by Candida albicans.


Subject(s)
Atorvastatin/pharmacology , Atorvastatin/therapeutic use , Candida albicans/drug effects , Candidiasis, Oral/drug therapy , Candidiasis, Vulvovaginal/drug therapy , Animals , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Azoles/pharmacology , Candidiasis, Oral/microbiology , Candidiasis, Vulvovaginal/microbiology , Disease Models, Animal , Drug Repositioning , Drug Resistance, Fungal , Female , Humans , Mice , Microbial Sensitivity Tests , Rats , Treatment Outcome
2.
Biomed Pharmacother ; 129: 110432, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32768935

ABSTRACT

Gastrointestinal diseases are very common problems; available treatments are very limited and come with a range of side effects. Coumarins are an extensive class of phenolic compounds that can be found in plants, fungi and bacteria. The 7-hydroxycoumarin, also known as umbelliferone (UMB), is a compound that comes from coumarin and has been showing biological activities in other studies. As of this scenario, the present study was designed to evaluate the acute oral toxicity, mutagenic, antidiarrheal, anti-bacterial, and antiulcerogenic effects, and antioxidant capacity of UMB. An investigation was conducted through the hippocratic screening method and through histopathological analysis in animals to evaluate the effects of acute oral administration of a dose of 50, 100 and 200 mg/kg of UMB. A micronucleus test on peripheral blood of Swiss mice, which were orally treated with three doses (50, 100 and 200 mg/kg), was conducted to evaluate mutagenic activities. The antiulcerogenic activity was accomplished through the ethanol-induced damage method. Antidiarrheal activities were tested for inducing diarrhea with castor oil and evaluating intestinal transit duration; additionally, the antimicrobial effect against some enteropathogenic bacteria was analyzed. Finally, the antioxidant capability was determined by the capacity of the UMB sample to kidnap the stable radical 2,2-diphenyl-1-picrylhydrazyl. Of the evaluated doses, signs of toxicity after acute administration of the compound were not observed. UMB presented antiulcerogenic activity (100 and 200 mg/kg), which was explained because of its antioxidant capacity. A gastro protective effect was similar to the positive control, and the UMB was able to significantly reduce intestinal transit, and also diarrheal symptoms. Furthermore, UMB had an anti-bacterial effect with minimum inhibitory concentration fluctuating between 62.5 and 1000 µg/mL. Based on these findings, we can suggest that UMB has important biological activities in vivo and in vitro and is not toxic under the evaluated circumstances, which demonstrates its large potential for pharmacological use.


Subject(s)
Anti-Ulcer Agents/pharmacology , Antidiarrheals/pharmacology , Diarrhea/prevention & control , Stomach Ulcer/prevention & control , Umbelliferones/pharmacology , Animals , Anti-Bacterial Agents/pharmacology , Anti-Ulcer Agents/toxicity , Antidiarrheals/toxicity , Bacteria/drug effects , Bacteria/growth & development , Castor Oil , Defecation/drug effects , Diarrhea/chemically induced , Diarrhea/physiopathology , Disease Models, Animal , Ethanol , Gastrointestinal Motility/drug effects , Male , Mice , Stomach/drug effects , Stomach/pathology , Stomach Ulcer/chemically induced , Umbelliferones/toxicity
SELECTION OF CITATIONS
SEARCH DETAIL